Global Angioedema Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

Allergic angioedema, Drug-induced angioedema, Idiopathic angioedema, and Hereditary angioedema (HAE)

By Treatment ;

Drugs Class, Antihistamines, Corticosteroids, Antigonadotropic agents, and Vasopressor

By Route Of Administration;

Injection and Oral

By End Use;

Hospitals, Clinics, and Research Organizations

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn140957482 Published Date: June, 2025 Updated Date: July, 2025

Angioedema Treatment Market Overview

Angioedema Treatment Market (USD Million)

Angioedema Treatment Market was valued at USD 2,976.51 million in the year 2024. The size of this market is expected to increase to USD 6,230.55 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 11.1%.


Global Angioedema Treatment Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 11.1 %


Study Period2025 - 2031
Base Year2024
CAGR (%)11.1 %
Market Size (2024)USD 2,976.51 Million
Market Size (2031)USD 6,230.55 Million
Market ConcentrationLow
Report Pages325
2,976.51
2024
6,230.55
2031

Major Players

  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V. (now part of Viatris Inc.)
  • Pharming Group NV
  • Fresenius Kabi AG
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Bausch Health Companies Inc.
  • Regeneron Pharmaceuticals, Inc.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Angioedema Treatment Market

Fragmented - Highly competitive market without dominant players


The Angioedema Treatment Market is gaining momentum as the number of individuals diagnosed with chronic and hereditary forms of angioedema increases. Approximately 35% of these patients require consistent therapeutic management using advanced preventive and acute treatment strategies. Better disease awareness and timely diagnosis are accelerating the demand for reliable treatment modalities.

Adoption of Targeted Biologic Treatments
There is a noticeable trend toward targeted therapies and biologics, especially monoclonal antibodies and C1 esterase inhibitors, which now account for nearly 40% of new prescriptions. These drugs offer enhanced efficacy with fewer adverse events, making them more attractive to physicians and patients seeking long-term relief and disease control.

Need for Rapid Relief Fuels On-Demand Solutions
Over 50% of patients report experiencing sudden and severe angioedema flare-ups, increasing the need for rapid-acting on-demand treatments. Products with faster onset times and improved delivery methods are capturing attention. Injectable therapies that quickly reduce symptoms are emerging as a standard for managing acute episodes effectively.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Treatment
    3. Market Snapshot, By Route of Administration
    4. Market Snapshot, By End Use
    5. Market Snapshot, By Region
  4. Angioedema Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Advancements in treatment options
        2. Increasing prevalence rates globally
        3. Rising awareness campaigns
        4. Technological innovations in therapies
        5. Growing healthcare expenditure
      2. Restraints
        1. Limited access to healthcare
        2. High treatment costs
        3. Stringent regulatory guidelines
        4. Side effects of medications
        5. Lack of trained professionals
      3. Opportunities
        1. Emerging markets expansion
        2. Development of novel therapies
        3. Collaborative research initiatives
        4. Personalized treatment approaches
        5. Increasing investments in R&D
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Angioedema Treatment Market, By Type, 2021 - 2031 (USD Million)

      1. Allergic angioedema

      2. Drug-induced angioedema

      3. Idiopathic angioedema

      4. Hereditary angioedema (HAE)

    2. Angioedema Treatment Market, By Treatment, 2021 - 2031 (USD Million)
      1. Drugs Class
      2. Antihistamines
      3. Corticosteroids
      4. Antigonadotropic agents
      5. Vasopressor
    3. Angioedema Treatment Market, By Route of Administration, 2021 - 2031 (USD Million)

      1. Injection

      2. Oral

    4. Angioedema Treatment Market, By End Use, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Clinics
      3. Research Organizations
    5. Angioedema Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Sanofi SA
      2. Teva Pharmaceutical Industries Ltd.
      3. Mylan N.V. (now part of Viatris Inc.)
      4. Pharming Group NV
      5. Fresenius Kabi AG
      6. Ionis Pharmaceuticals, Inc.
      7. Merck & Co., Inc.
      8. Bausch Health Companies Inc.
      9. Regeneron Pharmaceuticals, Inc.
  7. Analyst view
  8. Future Outlook of the Market